Inhibitors of the Elastase LasB for the Treatment of Pseudomonas aeruginosa Lung Infections

Autor: Jelena Konstantinović, Andreas M. Kany, Alaa Alhayek, Ahmed S. Abdelsamie, Asfandyar Sikandar, Katrin Voos, Yiwen Yao, Anastasia Andreas, Roya Shafiei, Brigitta Loretz, Esther Schönauer, Robert Bals, Hans Brandstetter, Rolf W. Hartmann, Christian Ducho, Claus-Michael Lehr, Christoph Beisswenger, Rolf Müller, Katharina Rox, Jörg Haupenthal, Anna K.H. Hirsch

Publikováno v: ACS Central Science, Vol 9, Iss 12, Pp 2205-2215 (2023)

Externí odkaz: https://doaj.org/article/ea30f522c5d744fdb5b1cfb4ff499d72

Discovery and Characterization of Synthesized and FDA-Approved Inhibitors of Clostridial and Bacillary Collagenases

Autor: Alaa Alhayek, Ahmed S. Abdelsamie, Esther Schönauer, Virgyl Camberlein, Evelyn Hutterer, Gernot Posselt, Jamil Serwanja, Constantin Blöchl, Christian G. Huber, Jörg Haupenthal, Hans Brandstetter, Silja Wessler, Anna K. H. Hirsch

Publikováno v: Journal of medicinal chemistry. 65(19)

In view of the worldwide antimicrobial resistance (AMR) threat, new bacterial targets and anti-infective agents are needed. Since important roles in bacterial pathogenesis have been demonstrated for the collagenase H and G (ColH and ColG) from

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c172d6c12ce42b4850093f0e86b4bcc
https://pubmed.ncbi.nlm.nih.gov/36154055

17β-Hydroxysteroid Dehydrogenase Type 1 Inhibition: A Potential Treatment Option for Non-Small Cell Lung Cancer

Autor: Rolf W. Hartmann, Chris J. van Koppen, Matthias W. Laschke, Giuseppe Felice Mangiatordi, Ahmed S. Abdelsamie, Martin Frotscher, Orazio Nicolotti, Abdelrahman Mohamed, Angelo Carotti, Arcangela Mazzini, Hanna Drzewiecka, Emanuele M. Gargano, Paweł P. Jagodziński, Sandrine Marchais-Oberwinkler

Publikováno v: ACS medicinal chemistry letters
United States
ACS Med Chem Lett
ACS medicinal chemistry letters (2021). doi:10.1021/acsmedchemlett.1c00462
info:cnr-pdr/source/autori:Emanuele M. Gargano, Abdelrahman Mohamed, Ahmed S. Abdelsamie, Giuseppe F. Mangiatordi, Hanna Drzewiecka, Pawe? P. Jagodzi?ski, Arcangela Mazzini, Chris J. van Koppen, Matthias W. Laschke, Orazio Nicolotti, Angelo Carotti, Sandrine Marchais-Oberwinkler, Rolf W. Hartmann, and Martin Frotscher/titolo:17?-Hydroxysteroid Dehydrogenase Type 1 Inhibition: A Potential Treatment Option for Non-Small Cell Lung Cancer/doi:10.1021%2Facsmedchemlett.1c00462/rivista:ACS medicinal chemistry letters/anno:2021/pagina_da:/pagina_a:/intervallo_pagine:/volume

[Image: see text] In the face of the clinical challenge posed by non-small cell lung cancer (NSCLC), the present need for new therapeutic approaches is genuine. Up to now, no proof existed that 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) is

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b72b1eb9a0d3948ea61df325c6e341e
https://hdl.handle.net/10033/623149

Design, synthesis, and biological evaluation of novel benzimidazole derivatives as sphingosine kinase 1 inhibitor

Autor: Fatma A.F. Ragab, Ahmed S. Abdelsamie, Sonam Roy, Anna K. H. Hirsch, Mohamed A. Omar, Shadia A. Galal, Imtaiyaz Hassan, Hoda I. El Diwani, Ahmad Abu Turab Naqvi, Sarah H. M. Khairat

Publikováno v: Archiv der PharmazieREFERENCES. 354(9)

Sphingosine kinase 1 (SphK1) has emerged as an attractive drug target for different diseases. Recently, discovered SphK1 inhibitors have been recommended in cancer therapeutics; however, selectivity and potency are great challenges. In this study, a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c03c87ef4a485b2b2b1234966b67f27
https://pubmed.ncbi.nlm.nih.gov/34128259

Highly Potent 17β-HSD2 Inhibitors with a Promising Pharmacokinetic Profile for Targeted Osteoporosis Therapy

Autor: Lorenz Siebenbuerger, Sandrine Marchais-Oberwinkler, Michael D. Menger, Martin Frotscher, Ahmed S. Abdelsamie, Carsten Boerger, Rolf W. Hartmann, Victor Hernandez-Olmos, Claudia Scheuer, Chris J. van Koppen, Matthias W. Laschke

Publikováno v: Journal of Medicinal Chemistry. 61:10724-10738

Intracellular elevation of E2 levels in bone by inhibition of 17β hydroxysteroid dehydrogenase type 2 (17β-HSD2) without affecting systemic E2 levels is an attractive approach for a targeted therapy against osteoporosis, a disease which is characte

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3a7ff0cde1f64d87d00e9445907fc28
https://doi.org/10.1021/acs.jmedchem.8b01373